Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs Of Clinical Benefit
Santaris Pharma announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously treated cancer patients with advanced malignancies. EZN-2968 is being evaluated in patients with solid tumors and lymphoma. The study data, which was presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting in Florida last week, demonstrated that EZN-2968 is well tolerated, and that early signs of clinical benefit - prolonged stable disease - were observed in several patients.
buy viagra
New Hampshire's Medicaid Program Almost Out Of Money
"Rising unemployment and spiking Medicaid and welfare caseloads have put [New Hampshire"s] most recent budget to the test just two weeks after its adoption," New Hampshire Public Radio reports. The state"s Medicaid caseload is just 39 enrollees away from putting the "state"s Medicaid budget in the red."
News of the day
Understanding Of Antidepressant Drugs Enhanced By New Mouse Model Of Depression/Anxiety
A recent study finds that the antidepressant effects of drugs like Prozac involve both neurogenesis-dependent and -independent mechanisms, a finding that may lead to development of better treatments for depression and anxiety. The research, published by Cell Press in the May 28th issue of the journal Neuron, utilizes a new experimental mouse model of depression/anxiety that is the first to permit simultaneous examination of multiple effects of antidepressant treatment in the same animal.
Nutrition

International Symposium On Atherosclerosis Highlights Latest Treatment Advancements

Atherosclerosis, or hardening of the arteries with plaque buildup, is the underlying cause of heart disease and stroke, which together account for more than half of all death and disability in developed nations. The world"s largest forum for new research on the topic, the International Symposium on Atherosclerosis (ISA), will hold its 15th triennial meeting at the John B. Hynes Veterans Memorial Convention Center in Boston, June 14 to 18. Organized under the auspices of the International Atherosclerosis Society and co-hosted by the Boston Atherosclerosis Society and Weill Cornell Medical College, the international Symposium -- the first held in the U.S. in 30 years -- will feature more than 1,500 scientific presentations and posters sessions, with invited speakers representing 25 countries and five continents. Registered attendees are coming from more than 60 countries. "Recent years have seen important advances in the diagnosis, treatment and prevention of atherosclerosis," says Dr. Antonio M. Gotto Jr., Symposium co-president and the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College. "The International Symposium on Atherosclerosis is a unique opportunity for the world"s top experts in this field to gather and share their latest research findings with the aim of reducing the impact of this disease." A leading authority on statins for the prevention and treatment of atherosclerosis, Dr. Gotto will chair a plenary session on inhibitors of cholesterol synthesis and absorption, and a clinical symposium on new developments in statin therapy. "New research into the nutritional, lifestyle, and genetic foundations of atherosclerosis, advanced imaging techniques, novel screening and diagnostic biomarkers, and better lifestyle and drug therapies are all helping to make major progress in the early detection, prevention, and treatment of this disease," says Dr. Ernst J. Schaefer, Symposium co-president, professor of medicine, and senior scientist and director of the Lipid Metabolism Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and Tufts University School of Medicine. "Our understanding of atherosclerosis and coronary heart disease has evolved from a primary focus on LDL cholesterol levels to the broader concept of cardiometabolic risk -- a grouping of risk factors that includes emerging markers such as intra-abdominal obesity and insulin resistance," says Dr. Jean-Charles Fruchart, president of the International Atherosclerosis Society. "New research, especially in genetics, is helping elucidate the complex mechanisms behind the disease, and introduce new ways to prevent and treat it." The 2009 International Symposium on Atherosclerosis will provide a comprehensive and up-to-date overview of recent advances in the field of atherosclerosis, including new insights and treatment strategies. For more information and a full schedule of presentations, visit http://www.isa2009.org. Weill Cornell Medical College


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009